Replimune Group Files 8-K

TL;DR

Replimune filed an 8-K, likely containing routine updates or disclosures.

AI Summary

Replimune Group, Inc. filed an 8-K on November 21, 2024, to report on other events and financial statements. The filing does not contain specific details on new agreements, material events, or financial figures within the provided text.

Why It Matters

This 8-K filing indicates that Replimune Group, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial data that would indicate a high-risk situation.

Key Players & Entities

• Replimune Group, Inc. (company) — Registrant
• November 21, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-38596 (identifier) — Commission File Number
• 82-2082553 (identifier) — IRS Employer Identification Number
• 500 Unicorn Park Drive Suite 303 Woburn , MA 01801 (address) — Address of principal executive offices
• ( 781 ) 222-9600 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar

Filing Documents

• tm2429181d1_8k.htm (8-K) — 29KB
• tm2429181d1_ex99-1.htm (EX-99.1) — 10KB
• 0001104659-24-121616.txt ( ) — 212KB
• repl-20241121.xsd (EX-101.SCH) — 3KB
• repl-20241121_lab.xml (EX-101.LAB) — 33KB
• repl-20241121_pre.xml (EX-101.PRE) — 22KB
• tm2429181d1_8k_htm.xml (XML) — 4KB

01 Regulation

Item 7.01 Regulation FD Disclosure. On November 21, 2024, Replimune Group, Inc. (the "Company") issued a news release announcing certain updates with respect to RP1, the Company's lead product candidate. A copy of such news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Item 7.01 and the accompanying Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The Company undertakes no obligation to update, supplement or amend the materials furnished herewith.

01 Other Events

Item 8.01 Other Events. On November 21, 2024, the Company issued a news release announcing that it has submitted a biologics license application to the U.S. Food and Drug Administration ("FDA") for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The submission was made under the Accelerated Approval pathway. The Company also announced that FDA has granted Breakthrough Therapy designation to RP1 in combination with nivolumab in the same setting.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 News Release dated November 21, 2024 104 Cover page interactive data file (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: November 21, 2024 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer